Unity Biotechnology (NASDAQ:UBX) Given New $4.00 Price Target at HC Wainwright

Unity Biotechnology (NASDAQ:UBX) had its price objective reduced by HC Wainwright from $8.00 to $4.00 in a report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Chardan Capital reissued a “buy” rating and issued a $6.00 price objective on shares of Unity Biotechnology in a research note on Monday, March 10th.

Unity Biotechnology Trading Down 28.8 %

UBX opened at $1.30 on Monday. The stock’s 50-day moving average price is $1.91 and its 200 day moving average price is $1.51. Unity Biotechnology has a 12-month low of $0.94 and a 12-month high of $3.10. The firm has a market cap of $21.93 million, a price-to-earnings ratio of -0.99 and a beta of 1.02.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Unity Biotechnology stock. Bridgeway Capital Management LLC boosted its stake in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) by 100.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,000 shares of the company’s stock after purchasing an additional 25,000 shares during the quarter. Bridgeway Capital Management LLC owned approximately 0.30% of Unity Biotechnology worth $49,000 as of its most recent SEC filing. 29.49% of the stock is owned by institutional investors and hedge funds.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.